CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$248.76M, lower than 95% of all stocks globally
- PositionGross margin is 99.4%, higher than 95% of its Biotechnology peers (median 77.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.00BUSDvs all stocks (USD)
Revenue (TTM)
42.16MUSDvs all stocks (USD)
Beta
0.0880xvs all stocks
52-Week Change
176.80%vs all stocks
Market Capitalization
9.00BUSDvs all stocks (USD)
Enterprise Value
7.84BUSDvs all stocks (USD)
Forward P/E
-20.97xvs Biotechnology peers
Price to Book (MRQ)
7.53xvs Biotechnology peers
Enterprise to Revenue
186.03xvs Biotechnology peers
Enterprise to EBITDA
-14.39xvs Biotechnology peers
Gross Margin
99.39%vs Biotechnology peers
Operating Margin
-527.35%vs Biotechnology peers
Return on Assets (TTM)
-26.28%vs Biotechnology peers
Return on Equity (TTM)
-42.45%vs Biotechnology peers
Revenue (TTM)
42.16MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4230USDUpdated Aug 27, 2026Quarterly Revenue Growth
2336.30%vs Biotechnology peers
Gross Profit (TTM)
-334.72MUSDvs all stocks (USD)
EBITDA (TTM)
-544.85MUSDvs all stocks (USD)
Net Income (TTM)
-501.61MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2336.28%vs Biotechnology peers
Operating Cash Flow (TTM)
-422.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-248.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.70MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.08MUSDFY2025 · Dec 31, 2025Gross Profit
6.62MUSDFY2025 · Dec 31, 2025Operating Income
-516.77MUSDvs all stocks (USD)
Pre-tax Income
-465.14MUSDFY2025 · Dec 31, 2025Income Tax Expense
180.00KUSDFY2025 · Dec 31, 2025Net Income
-465.32MUSDFY2025 · Dec 31, 2025EBIT
-516.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-512.88MUSDFY2025 · Dec 31, 2025Research & Development
332.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
191.33MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
51.99MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-465.32MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-375.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-380.78MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
102.34MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-465.32MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.89MUSDFY2025 · Dec 31, 2025Stock-based Compensation
91.02MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.01MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-592.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.04MUSDFY2025 · Dec 31, 2025Capital Expenditures
-5.76MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.00BUSDFY2025 · Dec 31, 2025Sale of Investments
1.18BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
173.91MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
105.77MSharesUpdated Aug 27, 2026Float Shares
95.50MSharesUpdated Aug 27, 2026Shares Short
6.59MSharesUpdated Aug 27, 2026Short Ratio
2.26daysvs all stocks
Short % of Shares Outstanding
7.26%vs all stocks
% Held by Insiders
1.57%vs all stocks
% Held by Institutions
120.03%vs all stocks
Total Cash (MRQ)
1.21BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.37USDUpdated Aug 27, 2026Total Debt (MRQ)
47.19MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0396xvs Biotechnology peers
Current Ratio (MRQ)
15.57xvs Biotechnology peers
Book Value per Share (MRQ)
11.27USDUpdated Aug 27, 2026Total Assets
1.13BUSDvs all stocks (USD)
Total Current Assets
1.05BUSDFY2025 · Dec 31, 2025Total Liabilities
134.17MUSDFY2025 · Dec 31, 2025Total Non-current Assets
77.92MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
49.10MUSDFY2025 · Dec 31, 2025Total Current Liabilities
85.07MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
101.54MUSDFY2025 · Dec 31, 2025Other Short-term Investments
926.35MUSDFY2025 · Dec 31, 2025Accounts Receivable
592.00KUSDFY2025 · Dec 31, 2025Inventory
2.02MUSDFY2025 · Dec 31, 2025Accounts Payable
22.61MUSDFY2025 · Dec 31, 2025Short-term Debt
6.49MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.24MUSDFY2025 · Dec 31, 2025Long-term Debt
42.05MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.24MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.41BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.42BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
992.08MUSDvs all stocks (USD)
52-Week Low
30.25USDUpdated Aug 27, 202652-Week High
84.88USDUpdated Aug 27, 202652-Week Change
176.80%vs all stocks
Beta
0.0880xvs all stocks
50-Day MA
70.88USDUpdated Aug 27, 2026200-Day MA
49.58USDUpdated Aug 27, 2026Avg 10-Day Volume
2.45MSharesUpdated Aug 27, 2026Avg 30-Day Volume
2.74MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
-5.05USDUpdated Aug 27, 2026Other Income / Expense
-357.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 99.4%, higher than 95% of its Biotechnology peers (median 77.2%)Significant
Gross margin: 0.99Industry median: 0.77Industry P95: 0.99Peers compared: 194
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$248.76M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -248,761,632Global P5: -209,187,555.994
Market cap is $9B, above the global median of $1.18BNotable
Market cap (USD): 9,001,117,192Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule